1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea Pharmaceutica's Preliminary FY21 Revenue Beats Estimates

01/10/2022 | 01:55am EDT


© MT Newswires 2022
All news about BASILEA PHARMACEUTICA AG
05/24TRANSCRIPT : Basilea Pharmaceutica AG Presents at UBS Global Healthcare Conference, May-24..
CI
04/27Basilea Pharmaceutica Licenses Antifungal Program From US-based Fox Chase
MT
04/27Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase..
AQ
04/27Basilea Pharmaceutica AG Announces Licensing of Novel First-In-Class Antifungal Program..
CI
04/13Basilea shareholders approve all proposals of the board of directors at the annual gene..
GL
04/13Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Boa..
CI
04/13Basilea's Oncology Drug Candidates Show Anti-Cancer Activity in Preclinical Trial
MT
04/13Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and ..
AQ
04/13Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891
CI
03/30BASILEA PHARMACEUTICA : Updated March 30, 2022
PU
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2022 126 M 131 M 131 M
Net income 2022 -42,0 M -43,6 M -43,6 M
Net Debt 2022 100 M 104 M 104 M
P/E ratio 2022 -9,73x
Yield 2022 -
Capitalization 393 M 409 M 409 M
EV / Sales 2022 3,93x
EV / Sales 2023 3,53x
Nbr of Employees 154
Free-Float 87,7%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 33,20 CHF
Average target price 77,00 CHF
Spread / Average Target 132%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-20.45%402
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569
ICON PUBLIC LIMITED COMPANY-30.17%17 581